Let’s Talk Less About Fear of Zohydro Addiction and More About What May Drive It, Says Trucueticals® Founder Reza Ghorbani, MD, ABIPP, FIPP
Washington, D.C. (PRWEB) February 27, 2014 -- The controversy over the FDA’s approval of Zohydro, a high potency prescription painkiller, is an opportunity to talk about the bigger picture of pain relief, not just the problem of drug addiction.
Diet, exercise and stress management are also valuable approaches that don’t expose patients to dangerous side effects.
“The okay of Zohydro for ‘pain severe enough to require daily around-the-clock treatment’ will comfort some, but may bring harm to others in the form of addiction,” says pain management specialist Reza Ghorbani, MD, ABIPP, FIPP. He’s the founder and CEO of Trucueticals® , maker of Noxicare products for natural pain relief.
Zohydro is one of a group of hydrocodone-containing drugs which the FDA wants doctors to prescribe more carefully, but those regulations are still pending. According to the Centers for Disease Control, nearly 15,000 people die every year from prescription drug overdoses.
Doctor Ghorbani-- among many other experts in the pain and addiction communities--says Zohydro’s approval should be reconsidered because of its potential for abuse and misuse. However, drugs aren’t topic ‘A’ in the pain conversation.
The drive to market more powerful analgesics like Zohydro sends a strong message that we’re not doing enough to treat the estimated 100-million Americans suffering from chronic pain.
“No question prescription that painkillers are a valuable tool when used appropriately. However, they’re just a bandage and not a cure. There are effective alternatives that are safe, natural and non-addictive, which are gaining popularity among patients and practitioners. Pain should be managed, not masked,” says Dr. Ghorbani.
Dr. Ghorbani is also the author of, “Secrets to a Pain Free Life”, available on Amazon.com.
Media Contact: Jeffrey Levine, Truceuticals Inc., http://www.noxicare.com, +1 (619) 300-5928, [email protected]
Share this article